Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | DRD4 | P21917 | 6/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795894 | 0.96 | KMT2A (0.43) | KMT2AMAPTHPGDMEN1KDM4E | |
| SCHEMBL1793900 | 0.94 | DRD2 (0.42) | KMT2AHTR1BDRD2DRD4DRD3 | |
| SCHEMBL1793087 | 0.94 | KMT2A (0.43) | KMT2AMAPTHPGDMEN1KDM4E | |
| SCHEMBL1793151 | 0.92 | MEN1 (0.44) | KMT2AMAPTHPGDMEN1KDM4E | |
| SCHEMBL1795534 | 0.90 | KMT2A (0.47) | KMT2AHTR1BDRD2DRD4DRD3 | |
| SCHEMBL1794541 | 0.90 | KMT2A (0.47) | KMT2AMAPTHPGDMEN1KDM4E | |
| SCHEMBL1799793 | 0.90 | GABRA1 (0.39) | KMT2AMAPTHPGDMEN1L3MBTL1 | |
| SCHEMBL1794258 | 0.88 | KMT2A (0.43) | KMT2AMAPTHPGDMEN1KDM4E | |
| SCHEMBL1792273 | 0.87 | HTR1B (0.41) | KMT2AMAPTHPGDMEN1KDM4E | |
| SCHEMBL1796170 | 0.86 | GABRA1 (0.41) | KMT2AMAPTHPGDMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | claimed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | claimed |
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | KMT2A 2287/4885MAPT 3330/4885HPGD 2230/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | KMT2A 2285/4885MAPT 3318/4885HPGD 2086/4885 |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRM1, CHRM3, CHRNA1 | KMT2A 1700/4885MAPT 2875/4885HPGD 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.